Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH-DMD phase 3 TAS-205 study in Duchenne muscular dystrophy
jRCT2041200055Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pizuglanstat in Duchenne muscular dystrophy (DMD) (3 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Mean change from baseline to Week 52 in time to rise from the floor and Incidence of adverse events and adverse reactions. Started Dec 2020; status: completed.
02
Drugs
pizuglanstat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2041200055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200055.